Sana Biotechnology (NASDAQ:SANA) Given Market Outperform Rating at JMP Securities

Sana Biotechnology (NASDAQ:SANA)‘s stock had its “market outperform” rating reaffirmed by analysts at JMP Securities in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $5.00 price target on the stock. JMP Securities’ price target indicates a potential upside of 90.62% from the company’s current price.

Other analysts also recently issued reports about the company. Citizens Jmp upgraded Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research note on Tuesday, March 18th. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Sana Biotechnology in a research note on Thursday, April 24th. Finally, Jefferies Financial Group started coverage on shares of Sana Biotechnology in a research report on Friday, March 14th. They issued a “buy” rating and a $7.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $9.83.

Sana Biotechnology Trading Up 0.9%

Shares of Sana Biotechnology stock opened at $2.62 on Tuesday. The business’s fifty day moving average price is $2.09 and its 200 day moving average price is $2.34. Sana Biotechnology has a twelve month low of $1.26 and a twelve month high of $7.40. The stock has a market capitalization of $591.43 million, a P/E ratio of -3.04 and a beta of 1.78.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. As a group, sell-side analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of SANA. Rhumbline Advisers raised its position in Sana Biotechnology by 5.4% in the first quarter. Rhumbline Advisers now owns 182,134 shares of the company’s stock worth $306,000 after acquiring an additional 9,359 shares in the last quarter. SCS Capital Management LLC bought a new stake in Sana Biotechnology during the first quarter worth approximately $137,000. Woodline Partners LP grew its position in Sana Biotechnology by 13.1% in the first quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock worth $1,312,000 after buying an additional 90,515 shares during the last quarter. Clearline Capital LP acquired a new stake in shares of Sana Biotechnology during the 1st quarter valued at $690,000. Finally, AQR Capital Management LLC boosted its stake in shares of Sana Biotechnology by 49.8% during the 1st quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock worth $963,000 after acquiring an additional 190,483 shares in the last quarter. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.